London Daily

Focus on the big picture.
Monday, Sep 22, 2025

The co-founder of BioNTech designed the coronavirus vaccine it made with Pfizer in just a few hours over a single day

The co-founder of BioNTech designed the coronavirus vaccine it made with Pfizer in just a few hours over a single day

BioNTech co-founder Ugur Sahin designed 10 different vaccine candidates over a single day in January. The FDA authorized one of them on Friday.

The Food and Drug Administration granted emergency authorization to Pfizer and BioNTech's coronavirus vaccine on Friday.

The two-dose vaccine is the first to be authorized in the US, though Moderna's coronavirus vaccine will likely receive FDA authorization this month as well.

After months of testing, the vaccine was found to be 95% effective in preventing COVID-19 in a large-scale trial. Its development process was unprecedentedly fast — no other vaccine in history has been created and manufactured so quickly. Previously, the fastest vaccine ever developed took more than four years.

But perhaps most remarkably, BioNTech co-founder Ugur Sahin designed the vaccine in just a few hours in mid-January, according to The Journal, a podcast from Gimlet and The Wall Street Journal.

A BioNTech spokesperson confirmed to Business Insider that Sahin — who founded the company with his wife, Özlem Türeci — made a "rough design over one weekend."

Moderna's vaccine also took just two days to design, as Business Insider previously reported. The reason both candidates could be designed so quickly comes down to the technology they rely on: messenger RNA, or mRNA.

The FDA had never approved an mRNA-based vaccine or treatment before. But now that the agency has granted authorization to Pfizer and BioNTech — with Moderna's likely to follow shortly — mRNA vaccines could set a new industry standard.

How mRNA vaccines train the body to fight the coronavirus


Messenger RNA is genetic material that tells cells how to make proteins. Pfizer's coronavirus vaccine candidate works by injecting a small piece of coronavirus mRNA into the body. That RNA codes for the virus' spike protein, which is what helps it attach to and invade cells. That's also what antibodies target and neutralize.

So the mRNA vaccine spurs the body to produce the spike protein internally in order to trigger that same immune response.

Moderna's candidate works in the same way and has been found to be 94.5% effective in trials.

Utilizing mRNA vaccine technology meant BioNTech and Moderna only needed the coronavirus' genetic sequence to design a vaccine. That's why they could move forward so quickly.

How BioNTech and Pfizer joined forces

The Pfizer facility in Pleasant Prairie, Wisconsin, on December 1, 2020.


On January 24, Sahin read a paper in The Lancet that described Chinese family members who traveled to Wuhan then contracted COVID-19.

"What was most concerning is that one of the family members had the virus and was virus-positive but did not have symptoms," Sahin told The Journal. This meant that the virus could be transmitted by asymptomatic carriers — and had probably already spread out of China.

"The math behind it just showed me it will happen, it's just a matter of a few weeks," Sahin said.

He decided to shift BioNTech's focus toward a coronavirus vaccine. The following week, Sahin told the company that operations going forward would be devoted mostly to developing and testing the vaccine.

Using the coronavirus' genetic sequence, which Chinese researchers published on January 11, Sahin designed 10 different candidates on his computer that weekend. One was the candidate later selected for larger trials — the one the FDA has authorized.

Sahin designed that winning candidate in just a few hours, according to The Journal.

But BioNTech, with a pre-pandemic workforce of 1,000, didn't have the capacity to manufacture the hundreds of thousands of doses needed for large-scale trials — let alone the hundreds of millions it would need if the vaccine worked.

So in February, Sahin called Pfizer's head of vaccine research, Kathrin Jansen; BioNTech had worked with Pfizer since 2018 on a flu vaccine.

"This is a disaster, and it's getting worse," Dr. Jansen told Dr. Sahin, according to The Wall Street Journal. "Happy to work with you."

The two companies announced their partnership in mid-March.


Kathrin Jansen, Pfizer's head of vaccine research and development.


Pfizer would manage the logistics, including manufacturing the vaccine in large batches and organizing the Phase 3 trial, which wound up involving 43,500 volunteers. BioNTech, meanwhile, handled the vaccine's design.

Pfizer and BioNTech announced that their vaccine was more than 90% effective on November 9. When Pfizer CEO Albert Bourla told told senior company officials of the findings, people jumped up from their chairs, The Wall Street Journal reported.

The full results of the Phase 3 trial were even stronger: The findings, published in the New England Journal of Medicine on Thursday, suggest that the vaccine doesn't trigger severe side effects in most people and is 95% effective at preventing COVID-19.

Anthony Fauci, the nation's leading infectious-disease expert, called the results "just extraordinary" and said they would "have a major impact on everything that we do with regard to COVID."

The speed at which BioNTech and Pizer developed the vaccine does not mean they sacrificed thoroughness, according to Albert Rizzo, chief medical officer for the American Lung Association.

"We're not skipping steps — we actually have better technology," Rizzo previously told Business Insider. "Why did it take two weeks to cross the Atlantic back in the 1800s? Well, we had to go on a boat. Whereas now, you can get across the ocean in several hours."

The pros and cons of mRNA vaccines


For decades, vaccines contained a dead or weakened version of a virus itself. Then early advances in genetics allowed vaccines to use proteins made by the virus instead. That method was first used in the 1980s to develop a vaccine for hepatitis B. Companies like Novavax are relying on the same protein-based model to create their coronavirus vaccine candidates.

But BioNTech was founded on the idea that mRNA could be used to develop cancer vaccines, hence its mRNA-based approach to the coronavirus. One of the company's senior vice presidents, biochemist Katalin Karikó, first discovered how to configure mRNA to be used in vaccines.


A volunteer receives an injection during South Africa's first human clinical trial for a potential vaccine against the coronavirus, at Baragwanath Hospital in Soweto, June 24, 2020.


Since RNA vaccines aren't cultivated using cells, they're quicker to produce.

The drawbacks of Pfizer and BioNTech's vaccine, however, are that people must get two injections three weeks apart, and it needs to be shipped at about -94 degrees Fahrenheit. That requires dry ice and special freezers.

Crucial questions about the vaccine also remain, like how long it will protect people from COVID-19 and whether it can prevent transmission and asymptomatic infection.

Newsletter

Related Articles

0:00
0:00
Close
Explosive Email Shows Sarah Ferguson Begged Forgiveness from Jeffrey Epstein After Taking His Money
Corrupt UK Politician Ed Davey Demands Elon Musk’s Arrest for Supporting Democracy
UK, Canada, and Australia Officially Recognise Palestine in Historic Shift
Alibaba Debuts Open-Source Deep Research Agent with Benchmarks Rivaling OpenAI
Marcos Faces Legacy-Defining Crisis as Flood Projects Scandal Sparks Massive Tide of Protests
China’s Micro-Drama Boom Turns Stalled Real Estate Projects into Lavish Film Sets
New Eye Drops Show Promise in Replacing Reading Glasses for Presbyopia
'Company Got 5,189 H-1B Visas, Then Laid Off 16,000 Americans': US Defends New $100,000 H-1B Visa Fee
Golf legend tells Omar she should be 'sent back to Somalia' after her Kirk comments
EU Set to Bar Big Tech from New Financial Data Access Scheme
China Bans Livestreaming and AI in Religion Amid Crackdown on Shaolin Temple Scandal
Documents Reveal Mandelson Failed to Declare Epstein-Funded Flights as MP in 2003
Dubai Property Boom Shows Strain as Flippers Get Buyer’s Remorse
Harris Memoir Sparks Backlash from Democrats for Blunt Critiques in ‘107 Days’
Germany Weighs Excluding France from Key European Fighter Jet Programme
Cyberattack Disrupts Check-in and Boarding Systems at Major European Airports
Japan’s ‘Death-Tainted’ Homes Gain Appeal as Prices Soar in Tokyo
Massive Attack Withdraws from Spotify Over Daniel Ek’s €600M Defence-AI Investment
Björn Borg Breaks Silence: Memoir Reveals Addiction, Shame and Cancer Battle
When Extremism Hijacks Idealism: How the Baader-Meinhof Gang Emerged and Fell
Top AI Researchers Are Heading Back to China as U.S. Struggles to Keep Pace
JWST Data Brings TRAPPIST-1e Closer to Earth-Like Habitability
Trump Orders Third Lethal Strike on Drug-Trafficking Vessel as U.S. Expands Maritime Counter-Narcotics Operations
Trump Orders $100,000 Fee on H-1B Visas and Launches ‘Gold Card’ Immigration Pathway
Why Google Search Is Fading and AI Is Taking Its Place
UAE-US Stargate Project Poised to Make Abu Dhabi a Global AI Powerhouse
Federal Judge Dismisses Trump’s Fifteen-Billion-Dollar Suit Against New York Times, Orders Refile
France’s Looming Budget Crisis and Political Fracture Raise Fears of Becoming Europe’s “Sick Man”
Three Russian MiG-31 Jets Breach Estonian Airspace in ‘Unprecedentedly Brazen’ NATO Incident
DeepSeek Claims R1 Model Trained for only $294,000, Sparking Global Debate Over China’s AI Capabilities
SoftBank Vision Fund to Cut Nearly Twenty Percent of Staff in Bold AI Strategy Shift
Intel’s Next-Gen Manufacturing Gets a Lifeline from Nvidia’s Strategic $5B Deal
Erika Kirk Elected CEO of Turning Point USA After Husband Charlie Kirk’s Assassination
Massive Strikes in France Pressure Macron and New PM on Austerity Proposals
Trump Seeks Supreme Court Permission to Remove Fed Governor Lisa Cook
Hillary Clinton’s Reckless Rhetoric Fuels Division After Charlie Kirk’s Assassination
NASDAQ Rises to Record as Intel Soars More Than 20%, Nvidia Gains 3%
Nvidia’s $5 Billion Bet on Intel Reshapes AI Hardware Landscape
Trump and Starmer Clash Over UK Recognition of Palestinian State Amid State Visit
Trump’s Quip on Biden and Google Lawsuit Revives Debate Over Antitrust Legacy
Macron and his wife to provide 'scientific photographic evidence' that she is a real woman
US Tech Giants Pledge Billions to UK AI Infrastructure Following Starmer's Call
Saudi Arabia cracks down on music ‘lounges’ after conservative backlash
DeepMind and OpenAI Achieve Gold at ‘Coding Olympics’ in AI Milestone
SEC Allows Public Companies to Block Investors from Class-Action Lawsuits
Saudi Arabia Signs ‘Strategic Mutual Defence’ Pact with Pakistan, Marking First Arab State to Gain Indirect Access to Nuclear Strike Capabilities in the Region
Federal Reserve Cuts Rates by Quarter Point and Signals More to Come
Effective and Impressive Generation Z Protest: Images from the Riots in Nepal
European manufacturers against ban on polluting cars: "The industry may collapse"
Sam Altman sells the 'Wedding Estate' in Hawaii for 49 million dollars
×